Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:56:52 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

BioArctic - Scientific progress and value creation

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

BioArctic - Scientific progress and value creation

2021-05-21 10:00:00

Redeye revisits BioArctic’s valuation based on recent advances in science and the company's steady value creation. We argue that easy and validated blood tests for Alzheimer's in primary care will expand the treatable patient population. We also account for the continuous value build-up in the company’s pipeline. Based on updated but still conservative assumptions, we calculate a fair value per share of SEK 208, a new bear case of SEK 50, and a bull case of SEK 400 per share. The company is greatly undervalued, in our view.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/